The estimated Net Worth of L M Stephenson is at least 198 千$ dollars as of 30 September 2005. L Stephenson owns over 5,500 units of Biodelivery Sciences International stock worth over 198,445$ and over the last 20 years L sold BDSI stock worth over 0$.
L has made over 2 trades of the Biodelivery Sciences International stock since 2004, according to the Form 4 filled with the SEC. Most recently L bought 5,500 units of BDSI stock worth 10,450$ on 30 September 2005.
The largest trade L's ever made was exercising 30,000 units of Biodelivery Sciences International stock on 18 November 2004 worth over 51,000$. On average, L trades about 11,833 units every 105 days since 2004. As of 30 September 2005 L still owns at least 35,500 units of Biodelivery Sciences International stock.
You can see the complete history of L Stephenson stock trades at the bottom of the page.
L's mailing address filed with the SEC is 2401 PENNSYLVANIA AVE., UNIT 5B 34, PHILADELPHIA, PA, 19130.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over 111,671,776$ worth of Biodelivery Sciences International stock and bought 1,813,177 units worth 5,352,510$ . The most active insiders traders include International, L.P. Elliott、Associates, L.P. Elliott、Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of 420,648$. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth 29,811$.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: